Search | Clinical Trials Finder

Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma
Interventions: Biospecimen Collection, Computed Tomography, Dexamethasone, Invasive Procedure, Magnetic Resonance Imaging, RAGE Antagonist FPS-ZM1, Resection; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diabetic Macular Edema
Interventions: Dexamethasone intravitreal implant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Irvine, California

Conditions: Obstructive Sleep Apnea
Interventions: Ketorolac, Standard of Care; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 18 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetic Macular Edema
Interventions: Dexamethasone, Sham injection, Laser Photocoagulation; Drug · Procedure
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Artesia, California

Conditions: Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma
Interventions: Floxuridine (FUDR), dexamethasone, Gemcitabine, Oxaliplatin, MRI, Research blood draws; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Cataract
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Topical prednisolone acetate; Drug
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Otorrhea, Otitis Media With Effusion in Children
Interventions: Otiprio, Ciprodex; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 6 Months to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pseudophakic Cystoid Macular Edema,, Diabetic Macular Edema
Interventions: Dexamethasone Implant; Drug
Lead sponsor: Northern California Retina Vitreous Associates; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
Interventions: Dextenza 0.4Mg Ophthalmic Insert; Drug
Lead sponsor: Kerry Assil, MD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Post-operative Pain, Opioid Use, Cleft Palate
Interventions: Quadratus lumborum block, Local anesthetic infiltration; Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 6 Years to 18 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Pharmacokinetics, Aqueous Dexamethasone, Inflammatory Cytokine Response
Interventions: Dexamethasone Ophthalmic implant; Drug
Lead sponsor: Frank A. Bucci, Jr., M.D.; Other
Eligibility: 55 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Wilkes-Barre, Pennsylvania

Conditions: Nerve Block, General Anesthesia, Spinal Anesthesia, Pain, Postoperative Nausea and Vomiting
Interventions: 25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block, 10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block, Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed, 45-60 mg of 1.5% mepivacaine for spinal anesthesia, LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia; Procedure · Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Macular Edema
Interventions: dexamethasone 700 ㎍ intravitreal implant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 18
States / cities: Phoenix, Arizona • San Francisco, California • Santa Ana, California + 15 more

Conditions: Rupture of Anterior Cruciate Ligament, Tear of Anterior Cruciate Ligament
Interventions: Mepivacaine, adductor canal continuous nerve catheter, Normal Saline as bolus followed by bupivacaine, adductor canal nerve block, ropivacaine and dexamethasone, Propofol, Fentanyl; Drug · Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 14 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cataract, Anterior Chamber Inflammation, Pain, Postoperative
Interventions: Dexamethasone phosphate, Placebo; Combination Product · Other
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Macular Edema
Interventions: Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone; Device · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more

Conditions: Colon Cancer, Rectal Cancer
Interventions: Floxuridine, Oxaliplatin, CPT-11; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Patients Having Undergone Unilateral Cataract Extraction and Implantation of a Monofocal
Interventions: Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA; Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Macular Edema, Fibrosis of the Retina
Interventions: Ozurdex, Surgery, Anterior Chamber (AC) Tap; Drug · Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epiretinal Membrane, Macular Edema
Interventions: Dexamethasone Intravitreal Implant; Drug
Lead sponsor: Barnes Retina Institute; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Chesterfield, Missouri • St Louis, Missouri

Conditions: Ocular Disease Requiring Surgery
Interventions: DEXTENZA®; Drug
Lead sponsor: Nathan Steinle; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Paso Robles, California • San Luis Obispo, California • Santa Maria, California

Conditions: Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
Interventions: Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Laboratory Biomarker Analysis, Oxaliplatin, Placebo Administration, Questionnaire Administration, Rituximab, Decitabine, Biospecimen Collection, Core Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Positron Emission Tomography, Magnetic Resonance Imaging, Central Venous Cannula Insertion, Portacath Placement, Computed Tomography; Dietary Supplement · Drug · Other + 2 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2033
U.S. locations: 4
States / cities: Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more

Conditions: Cataract
Interventions: Dextenza 0.4Mg Ophthalmic Insert; Drug
Lead sponsor: Iworks Laser and Vision Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Macromastia (Symptomatic)
Interventions: Pectoral II Nerve Block, Post Operative Pain Relievers; Procedure · Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Roanoke, Virginia

Search by objective public record fields.

FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma

Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

Effect of Ketorolac on Post Adenotonsillectomy Pain

Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema

Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery

Otiprio Versus Ciprodex Tympanostomy Tube Outcomes

Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery

Dextenza Within Upper Lid Canaliculus Compared With Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With PCIOL.

QL vs LAI for Palatoplasty

Pharmacokinetics of Aqueous Dexamethasone

Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery.

An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

Trial Evaluating Postop Pain and Muscle Strength Among Regional Anesthesia Techniques for Ambulatory ACL Reconstruction

Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer

OPEN-LABEL, MULTI-CENTER, PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPHTHALMIC SOLUTION IN PATIENTS HAVING UNDERGONE CATARACT SURGERY WITH IMPLANTATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS (IOL)

Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases

Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane

INtravitreal and Aqueous Dexamethasone Levels After DEXtenza

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL.

Pectoral Block in Breast Reduction for Pain Control